SUNPHARMA
Sun Pharmaceutical Industries Limited · NSE:SUNPHARMA
1,777.70 INR16.70 +0.95%
Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) last traded at 1,777.70 INR, up 0.95% on the day. Over the past year the stock is up 3.61%. Its 52-week range is 1,583.70 to 2,046.90. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open1,769.00
Day range1,766.20 – 1,855.00
52-week range1,583.70 – 2,046.90
Volume5.13 M
Average volume (10 days)1.80 M
Market cap (USD)44.78 B
P/E38.90
EPS (TTM) (USD)0.4761
Dividend yield0.90%
Beta (1 year)0.2531
Revenue (TTM) (USD)6.42 B
Employees28.93 K
Performance
+1.16%1 week
−4.49%1 month
−11.84%3 months
+0.38%6 months
+3.35%Year to date
+3.61%1 year
Technical rating
Neutral
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Analysts’ target
2,188.70 INR
The average 1-year price target, +23.12% from the last price. See the forecast
Latest headlines
- Key facts: NSE:SUNPHARMA Q2 profit -36.4%; India sales +17.3%; Rs1,269crTradingView · 02 Nov 2026
- Sun Pharma shares in focus as management reiterates FY27 guidance; Analysts see up to 31% upsideCNBC TV18 · 02 Nov 2026
- Weekly Recap: Rs1,269cr charge and India formulations revenue +17.3%TradingView · 02 Nov 2026
- Sun Pharma shares gain despite Q2 profit slips 36% YoY | Should you buy, sell or hold? What brokerage says, target priceMint · 01 Nov 2026
- Ophthalmic products recalled: Why drug regulators ordered Sun Pharma to halt eye-drop production at Assam plant?Mint · 31 Oct 2026
- Sun Pharma Ordered To Halt Eye Drug Output At Assam PlantBusinessworld · 31 Oct 2026
- Sun Pharma taking remedial action, following voluntary withdrawal of 11 eye drops: ManagementBusiness Line · 30 Oct 2026
- SUNPHARMA: Sales rose 11.8%; India growth offset U.S. pressure from lenalidomide erosion and slower ILUMYAQuartr · 30 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.